Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs

Journal of Immunotherapy

Volumn 36, Issue 4, 2013, Pages 258-267

  Biragyn, Arya ^a   Bodogai, Monica ^a   Olkhanud, Purevdorj B ^a   Denny Brown, Sinan R ^a   Puri, Nitin ^b   Ayukawa, Koichi ^c   Kanegasaki, Shiro ^c   Hogaboam, Cory M ^d   Wejksza, Katarzyna ^a   Lee Chang, Catalina ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b APPLIED BIOSYSTEMS   (United States)

^c Effector Cell Institute Inc   (Japan)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

chemokine; FoxP3; IL10; metastasis; siRNA delivery; Tregs

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHEMOKINE RECEPTOR CCR4; INTERLEUKIN 10; SMALL INTERFERING RNA; TARC ARP; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CD8+ T LYMPHOCYTE; CHEMOTAXIS; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO GENE TRANSFER; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RNA INTERFERENCE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL17; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INTERLEUKIN-10; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, CCR4; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84875984259     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318294357c     Document Type: Article

References (41)

1. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
2. Valmori D, Merlo A, Souleimanian NE, et al. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest. 2005;115:1953-1962. (Pubitemid 40979735)
3. Rubtsov YP, Niec RE, Josefowicz S, et al. Stability of the regulatory T cell lineage in vivo. Science. 2010;329:1667-1671.
4. Jonuleit H, Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-1294. (Pubitemid 32524778)
5. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253-257. (Pubitemid 37323210)
6. Josefowicz SZ, Niec RE, Kim HY, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature. 2012;482:395-399.
7. Kleinewietfeld M, Puentes F, Borsellino G, et al. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood. 2005;105:2877-2886. (Pubitemid 40446282)
8. Levings MK, Roncarolo MG. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol. 2000;106:S109-S112. (Pubitemid 30482844)
9. Baatar D, Olkhanud PB, Wells V, et al. Tregs utilize beta-galactoside- binding protein to transiently inhibit PI3K/p21ras activity of human CD8 + T cells to block their TCR-mediated ERK activity and proliferation. Brain Behav Immun. 2009;23: 1028-1037.
10. Baatar D, Olkhanud P, Sumitomo K, et al. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4 + Tregs and unprimed CCR4-Tregs, regulate effector T cells using FasL. J Immunol. 2007;178:4891-4900. (Pubitemid 46595271)
11. Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589-601. (Pubitemid 39370513)
12. Gondek DC, Lu LF, Quezada SA, et al. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol. 2005;174:1783-1786. (Pubitemid 40223916)
13. Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity. 2008;28:870-880.
14. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmentalinterfaces. Immunity. 2008;28:546-558.
15. McLachlan JB, Catron DM, Moon JJ, et al. Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity. 2009;30:277-288.
16. Zou L, Barnett B, Safah H, et al. Bone marrow is a reservoir for CD4+ CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 2004;64:8451-8455. (Pubitemid 39491786)
17. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001;194:847-853. (Pubitemid 32983019)
18. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69:2000-2009.
19. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10: 942-949. (Pubitemid 39273735)
20. Olkhanud PB, Baatar D, Bodogai M, et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 2009;69:5996-6004.
21. Byrne WL, Mills KH, Lederer JA, et al. Targeting regulatory T cells in cancer. Cancer Res. 2011;71:6915-6920.
22. Powell DJ Jr, Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol. 2007;179:4919-4928.
23. Schiavo R, Baatar D, Olkhanud P, et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood. 2006;107:4597-4605. (Pubitemid 43882603)
24. Baatar D, Olkhanud P, Newton D, et al. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol. 2007;179:1996-2004.
25. Lelekakis M, Moseley JM, Martin TJ, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17:163-170. (Pubitemid 29335443)
26. Le Pogam S, Chua PK, Newman M, et al. Exposure of RNA templates and encapsidation of spliced viral RNA are influenced by the arginine-rich domain of human hepatitis B virus core antigen (HBcAg 165-173). J Virol. 2005;79:1871-1887. (Pubitemid 40459132)
27. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336. (Pubitemid 36432314)
28. Olkhanud PB, Rochman Y, Bodogai M, et al. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol. 2011;186:5656-5662.
29. Olkhanud PB, Damdinsuren B, Bodogai M, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res. 2011;71:3505-3515.
30. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964. (Pubitemid 44498003)
31. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666. (Pubitemid 41817714)
32. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709-717. (Pubitemid 41716361)
33. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res. 2000;2:331-334. (Pubitemid 32223615)
34. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005;65:11743-11751. (Pubitemid 41821736)
35. Bunt SK, Sinha P, Clements VK, et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284-290. (Pubitemid 43023273)
36. Barao I, Hanash AM, Hallett W, et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4 + CD25+ regulatory T cells. Proc Natl Acad Sci USA. 2006;103:5460-5465.
37. Smyth MJ, Teng MW, Swann J, et al. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol. 2006;176:1582-1587. (Pubitemid 43134302)
38. Terme M, Chaput N, Combadiere B, et al. Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol. 2008;180:4679-4686.
39. Loser K, Apelt J, Voskort M, et al. IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol. 2007;179:365-371. (Pubitemid 46986553)
40. Endharti AT, Rifa'I M, Shi Z, et al. Cutting edge: CD8 + CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J Immunol. 2005;175:7093-7097. (Pubitemid 41713400)
41. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, et al. CD25+ CD4 + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol. 2001;166:3008-3018. (Pubitemid 33117296)